Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Status:
Recruiting
Trial end date:
2038-05-01
Target enrollment:
Participant gender:
Summary
Patients eligible for this study have a type of blood cancer called T-cell leukemia or
lymphoma (lymph gland cancer).
The body has different ways of fighting infection and disease. This study combines two
different ways of fighting disease with antibodies and T cells. Antibodies are types of
proteins that protect the body from bacterial and other diseases. T cells, or T lymphocytes,
are special infection-fighting blood cells that can kill other cells including tumor cells.
Both antibodies and T cells have been used to treat cancer; they have shown promise, but have
not been strong enough to cure most patients.
T cells can kill tumor cells but there normally are not enough of them to kill all the tumor
cells. Some researchers have taken T cells from a person's blood, grown more of them in the
laboratory and then given them back to the person.
The antibody used in this study is called anti-CD7. This antibody sticks to T-cell leukemia
or lymphoma cells because of a substance on the outside of these cells called CD7. CD7
antibodies have been used to treat people with T-cell leukemia and lymphoma. For this study,
anti-CD7 has been changed so that instead of floating free in the blood it is now joined to
the T cells. When an antibody is joined to a T cell in this way it is called a chimeric
receptor.
In the laboratory, investigators have also found that T cells work better if they also add
proteins that stimulate T cells, such as one called CD28. Adding the CD28 makes the cells
grow better and last longer in the body, thus giving the cells a better chance of killing the
leukemia or lymphoma cells.
In this study, investigators attach the CD7 chimeric receptor with CD28 added to it to T
cells. Investigators will then test how long the cells last. These CD7 chimeric receptor T
cells with CD28 are investigational products not approved by the Food and Drug
Administration.
Phase:
Phase 1
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Center for Cell and Gene Therapy, Baylor College of Medicine Texas Children's Hospital The Methodist Hospital Research Institute The Methodist Hospital System